What do clinicians need to watch for with direct‐acting antiviral therapy?

Abstract

IntroductionThe introduction of drugs targeting the virus replication cycle has revolutionized treatment of chronic hepatitis C virus. These drugs, called direct‐acting antivirals, have brought about extremely high rates of virological cure and have increased the number of patients who can receive treatment due to the lack of absolute contraindications. A combination of different classes of direct‐acting antivirals is the current standard of care. Although treatment administration and monitoring has been simplified in recent years, it is still relatively complex and mostly in the hands of specialists. Several factors must be assessed before starting treatment to maximize efficacy and minimize side effects of treatment. In this review, we describe the factors that impact on the efficacy and safety of antiviral treatment for hepatitis C and provide clear recommendations for clinicians prescribing direct‐acting antivirals.MethodsWe reviewed literature to define best practice, based on factors associated with treatment efficacy and safety data to recommend treatment options, baseline and on‐treatment assessments. The review included searches in PubMed, and the abstracts presented at the International Liver Congress TM and The Liver Meeting TM between January 2013 and September 2017.ResultsClinical features that must be assessed before starting treatment include virological factors, such as hepatitis C virus genotype, HIV and hepatitis B coinfection and host factors, such as concomitant medications, liver disease stage and renal function.ConclusionsPatients who start antiviral treatment for chronic hepatitis C require a thorough clinical evaluation. There is a need for assessing factors that impact on the treatment schedule and duration or affect the pharmacokinetics of direct‐acting antivirals.

Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: A systematic review with meta-analysis

“…People with HIV and/or HBV coinfections and other comorbidities (e.g. haemophilia, thalassemia, kidney disfunction) should be referred to specialists [42,43].…”

“…Specialists will be necessary to manage patients with specific clinical conditions (e.g. cirrhosis, coinfections, and comorbidities) to reduce the adverse events and improve the treatment efficacy in these cases [40,42,43]. Innovative decentralization strategies could be implemented to improve access to HCV treatment, especially in resource-limited settings, contributing to the achievement of HCV elimination targets.…”

A Bimolecular Multicellular Complementation System for the Detection of Syncytium Formation: A New Methodology for the Identification of Nipah Virus Entry Inhibitors

“…In general, the treatment of viral infections often relies on anti-viral small molecules. Direct-acting antivirals (DTA) (antivirals that target the virus life cycle) are tremendously efficacious on blocking the viral replication [48]. Unfortunately, we have a very limited range of DTA at our disposal.…”

A Bimolecular Multicelular complementation system for the detection of syncytium formation: A new methodology for the identification of entry inhibitors

“…Direct-acting antivirals (DTA), that is to say, antivirals that target the virus life cycle, are tremendously efficacious on blocking the viral replication [44] . Unfortunately, we have a very limited range of DTA at our disposal.…”